Artificial Gastric Fluid Disintegration Test: Principles, Methods, and Applications

The artificial gastric fluid disintegration test is a standardized laboratory procedure used to evaluate how rapidly tablets, capsules, and other solid oral dosage forms break down under simulated stomach conditions. By replicating gastric temperature, pH, and mechanical agitation, the test provides essential data for pharmaceutical quality control, health food registration, and formulation development. This article explains the principles, sample types, testing items, methodology, acceptance criteria, and practical applications of the test.

Technical Overview

The artificial gastric fluid disintegration test measures the time required for a solid oral dosage form to fragment completely when immersed in a medium that simulates human gastric juice. Disintegration is defined as the state in which no palpable firm core remains, and any residual residue, other than insoluble coating fragments or soft mass of shell fragments, passes through the mesh screen of the test apparatus. The test does not demonstrate full dissolution of the active ingredients; rather, it confirms that the formulation breaks apart fast enough to release its contents for subsequent dissolution and absorption in the gastrointestinal tract.

Artificial gastric fluid is an acidic medium, typically prepared from dilute hydrochloric acid with or without the enzyme pepsin, adjusted to a pH of approximately 1.2 to 1.5 to reflect the fasting-state stomach environment. The test is performed at 37.0 ± 0.5 °C using a reciprocating basket-rack assembly that simulates the mechanical forces of gastric peristalsis. The procedure is harmonized across major pharmacopoeias, including the Chinese Pharmacopoeia (general chapter 0921), the United States Pharmacopoeia (USP <701>), and the European Pharmacopoeia (Ph. Eur. 2.9.1), with minor differences in apparatus dimensions and cycle rates.

Testing Samples

Conventional Tablets

Uncoated tablets, film-coated tablets, sugar-coated tablets, chewable tablets, and effervescent tablets can be evaluated in artificial gastric fluid. Coated tablets are of particular interest because the coating layer may delay water penetration and slow fragmentation. Effervescent and orally disintegrating formulations are usually tested in plain water, but gastric fluid testing is applied when acid-triggered release is relevant to the product design.

Hard and Soft Capsules

Hard gelatin and hard HPMC (vegetable) capsules are tested to confirm that the shell ruptures and releases the fill material within the specified time. Soft capsules (softgels) are especially dependent on the gastric medium, since the elastic shell must first hydrate, swell, and rupture in acid before the liquid or semi-solid fill can escape. Testing in gastric fluid also reveals cross-linking defects in gelatin shells, a stability problem that slows or prevents shell rupture.

Granules, Pellets, and Powders

Multi-unit formulations such as granules, pellets, and sachet powders can be assessed in a modified apparatus to verify that agglomerates disperse and disintegrate rather than forming persistent clumps in the acidic environment.

Health Foods and Dietary Supplements

Tablets and capsules of health foods, functional foods, and nutraceuticals are frequently subjected to artificial gastric fluid disintegration testing during product registration, filing, and quality control to demonstrate that the product will release its functional ingredients under physiological conditions.

Enteric-Coated and Delayed-Release Products

For acid-labile or gastric-irritant products, artificial gastric fluid is used as the acid stage of the test. The dosage unit must resist disintegration during the acid phase before being transferred to a phosphate buffer at pH 6.8 to confirm intestinal release.

Testing Items

The artificial gastric fluid disintegration test typically evaluates the following parameters:

• Disintegration time: the interval between immersion of the dosage unit in the medium and complete disintegration, recorded for each individual unit.
• Completeness of disintegration: confirmation that no firm, palpable core remains and that all parts of the unit pass through the mesh screen, with the exception of fragments of insoluble coatings or shell membranes.
• Residue characteristics: the appearance, texture, and quantity of any remaining fragments, which provide clues about formulation defects such as over-hardened binder, excessive coating, or gelatin cross-linking.
• Acid resistance: for enteric-coated products, evidence that the unit shows no disintegration or cracking during the specified acid-stage exposure.
• Batch-to-batch consistency: comparison of disintegration profiles across production batches to verify process control.

Testing Methods

Preparation of Artificial Gastric Fluid

Artificial gastric fluid without enzyme is prepared by diluting hydrochloric acid with purified water to obtain a solution of pH 1.2 to 1.5. An enzymatic version is prepared by dissolving a defined quantity of pepsin in the diluted acid solution. The enzymatic medium is used for products containing proteinaceous materials or when the standard medium causes gelatin shell cross-linking, since pepsin digests the cross-linked protein matrix. The medium is degassed if necessary and equilibrated to 37.0 ± 0.5 °C before testing.

Apparatus

The test uses a disintegration tester equipped with a basket-rack assembly. The assembly consists of six open-ended glass tubes, each holding one dosage unit, seated on a stainless-steel mesh screen. A perforated disc may be placed on top of each unit to keep it immersed and to provide additional mechanical stress. The assembly is immersed in a one-liter beaker of medium and reciprocated vertically at a frequency of approximately 30 to 35 cycles per minute through a stroke of roughly 50 to 60 mm.

Procedure

One dosage unit is placed in each of the six tubes, discs are added if specified, and the assembly is lowered into the medium at 37 °C. The operator observes the units throughout the run and records the time at which each unit fully disintegrates. If any unit fails to disintegrate within the limit, the pharmacopoeial retest scheme is applied: additional units are tested, and the batch passes if the total number of failures across all tested units does not exceed the allowable limit, typically no more than 2 failures out of 18 units.

Typical Acceptance Limits

Unless otherwise stated in the individual product monograph or registered specification, commonly specified limits include:

• Uncoated tablets: 15 to 30 minutes.
• Film-coated tablets: 30 minutes.
• Sugar-coated tablets: 60 minutes.
• Hard capsules: 30 minutes.
• Soft capsules: 60 minutes.
• Effervescent tablets: 5 minutes.
• Enteric-coated products: no disintegration or cracking within 120 minutes in acid, followed by complete disintegration within 60 minutes in pH 6.8 buffer.

Exact limits must always be confirmed against the current edition of the applicable pharmacopoeia or the approved product specification.

Applications

The artificial gastric fluid disintegration test supports a wide range of activities across pharmaceutical and food science:

• Quality control and batch release testing for tablets and capsules in manufacturing facilities.
• Formulation development, including screening of binders, disintegrants, coating systems, and capsule shell materials.
• Detection of gelatin cross-linking induced by processing conditions, excipient interactions, or long-term storage.
• Regulatory submissions, including new drug applications, generic product registration, and health food filing and registration dossiers.
• Stability studies, where disintegration is monitored over time to detect aging-related release failures.
• Comparative evaluations between generic and reference-listed products, or between different suppliers of the same dosage form.
• Verification of enteric and delayed-release coating integrity for acid-sensitive active ingredients.

FAQ

What is the difference between disintegration and dissolution testing?

Disintegration testing verifies that a dosage form breaks apart into small fragments within a set time, while dissolution testing quantifies the rate and extent to which the active ingredient dissolves into the medium. Disintegration is a physical breakdown test and is generally faster and less analytically demanding; it serves as a prerequisite indicator for reliable dissolution and absorption.

Why is the test performed at 37 °C?

37 °C corresponds to normal human body temperature. Maintaining the medium at 37.0 ± 0.5 °C ensures that the swelling, hydration, and rupture behavior of the dosage form reflects in vivo conditions.

Should pepsin be included in the artificial gastric fluid?

The choice depends on the product and the applicable standard. Non-enzymatic dilute hydrochloric acid is adequate for most conventional products. Pepsin-containing medium is preferred when protein-based ingredients or gelatin shells are involved, or when non-enzymatic medium produces failures due to cross-linked gelatin that do not reflect true in vivo behavior.

What should be done if a capsule floats during the test?

Floating units should be retained with a perforated disc, which keeps the dosage unit fully immersed and subjects it to consistent mechanical stress, ensuring a valid and reproducible measurement.

Which standards govern the artificial gastric fluid disintegration test?

The principal standards are the Chinese Pharmacopoeia general chapter 0921, USP general chapter <701>, and Ph. Eur. chapter 2.9.1. Health food and nutraceutical programs may also impose product-specific disintegration limits in their registration guidelines, and manufacturers should always test against the specification approved for their particular product.